Cambridge University Press 978-1-108-43671-7 — Evidence-Based Diagnosis 2Nd Edition Index More Information
Total Page:16
File Type:pdf, Size:1020Kb
Cambridge University Press 978-1-108-43671-7 — Evidence-Based Diagnosis 2nd Edition Index More Information Index AAA. See abdominal aortic adjustment from anchor, in AUROC. See area under an aneurysm probability estimates, ROC curve ABCD2 Score, 339–40 310–11 AUSTRI trial, 216–17 ® abdominal aortic aneurysm Advair inhaler, 216–17 authors, of randomized trials, (AAA), reliability of age at first birth, college 206 testing for, 338 education and, 349 autism spectrum disorder with screening tests, 350 ALND. See axillary lymph node (ASD), 354–5 absolute risk increase (ARI), dissection autonomy, clinician, 306–7 221–2 α, 281 availability, in probability absolute risk reduction (ARR), Altman, Douglas, 290 estimates, 310 3, 215–17, 221–2 ambiguous test results, average standard deviation, 123 confidence intervals around, spectrum bias from axillary lymph node dissection 292–3 exclusion of, 86–97 (ALND), 79–80, 318–56 black belt, 295 American Cancer Society, blue belt, 294 305–6 B. See cost of failing to treat brown belt, 294–5 amoxicillin bacteremia green belt, 293–4 for bacteremia in newborns, classification trees for, 183, white belt, 293 292–5 185 yellow belt, 293 for OME, 344–5 in newborn, 5, 47–8 accuracy, 8–9, 12, 319–20 amylase, serum, 78–80 confidence intervals in in diagnostic test studies, anchoring bias, 311–12 negative studies of, 292–5 76–80 anticholinergic medication, for posterior probability for reliability in lieu of, 110 enuresis, 345–6 multi-level tests of, 60 of risk predictions antidepressants regret graphs for, 63–4 calibration in, 147–9, prenatal, 354–5 ROC curve and, 48–51, 55 152–67, 338–9 randomized trials with, bacterial meningitis discrimination in, 146, confidence intervals in, bias in diagnostic test studies 150–67, 338–9 353–4 of, 330 NRI and IDI for, 165–6 appendicitis classification trees for, 183, quantification of, 146–67, partial verification bias and, 185 338–9 83 ROC curve and, 51–2 recalibration and, 154 reliability of testing for, 333 base-rate neglect, 309, 311–12 ® acetaminophen (Tylenol ), speed bumps as diagnostic Bayes, Thomas, 3 355–6 tool for, 332 Bayesian statistical analysis. See ACI-TIPI. See Acute Coronary WBC count for, 313 also posterior Ischemia–Time area under an ROC curve probability; prior Insensitive Predictive (AUROC), 51 probability Instrument discrimination in risk of clinical trials, 291–2 acute cardiac ischemia, wall predictions and, 150–67 confidence intervals and, 290 motion abnormalities as Wilcoxon Rank Sum test P-values and, 282–4 test for, 80, 329 and, 54–5 benefit per bad outcome Acute Coronary ARI. See absolute risk increase prevented (BBOP), Ischemia–Time ARR. See absolute risk 218–21 Insensitive Predictive reduction β, 281 Instrument (ACI-TIPI), ASD. See autism spectrum between-group comparisons, in 192–3 disorder randomized trials, 214 acute ligamentous knee injury, 2 as-treated analysis, 211–13 bias ADHD. See attention deficit- attention deficit-hyperactivity anchoring, 311–12 hyperactivity disorder disorder (ADHD), 348 cognitive, 311 357 © in this web service Cambridge University Press www.cambridge.org Cambridge University Press 978-1-108-43671-7 — Evidence-Based Diagnosis 2nd Edition Index More Information Index bias (cont.) blinding, in randomized trials, for ICU Mortality confirmation, 311 208–9, 345 Probability Model, in diagnostic test studies, 78 blue belts, 294 153–67 application of, 100–1 BMD. See bone mineral density for low back pain, 152 differential verification, BNP. See B-type natriuretic mean bias, MAE, and Brier 81–2, 86–8, 329–30 peptide Score for, 147–9, 338–9 double gold standard, body packing, reliability of recalibration and, 154 81–2, 86–8, 329–30 testing for, 333–8 ROC curves compared imperfect gold standard, bone mineral density (BMD), with plots of, 151–67 81–2, 89–91, 330–2 test–retest reliability in, cancer screening tests incorporation, 78–82, 329 127–9 differential verification bias partial verification, 80–5, Bonferroni correction, 287–9 in, 86 330 in antidepressant in EBM, 304–6 spectrum, 81–2, 86–97, randomized trials, overdiagnosis in, 263–5 330 353–4 total v. cause-specific falsification tests for, 236–8, bootstrap aggregation, 196 mortality in, 266–9 348 branch, of classification trees, cannabinoid hyperemesis immortal time, 242, 349 181–2 syndrome, 308 mean, 147–9, 338–9 BRCA testing, referral Cardiac Arrhythmia in post-test probability screening tool for, Suppression Trial, 252 estimates, 311–13 321–39 cardiovascular disease in pre-test probability breast cancer, 5, 269–70 risk predictions for, 341–2 estimates, 309–11 ALND for staging of, 79–80, vitamin E for prevention of, publication, 161–2 318–56 231–2, 237 in randomized trials, 215 BRCA referral screening tool case-control sampling, 12–14, in screening test studies, for, 321–39 321 258–68 EBM and screening of, 304–6 in diagnostic test studies, lead-time, 260–1 likelihood ratios applied to, 75–7 length-time, 261–2 16–17, 21 categorical variables pseudodisease, 263–6 risk prediction studies for, disease definition and, 93–5 slippery linkage, 267–8 163 inter-observer agreement for, stage migration, 261–3, stage migration bias and, 111–21, 332–8 353 262–3 category-free NRI, 165–6 sticky diagnosis, 258–68 2×2 table method applied to, cause-specific mortality, total volunteer effect, 259–60 15–16 mortality v., 266–9 spectrum breast development, reliability CBOP. See cost per bad in bacterial meningitis of staging of, 131 outcome prevented findings, 330 unbalanced disagreement CDC. See US Centers for definition of, 81–2, 91–3 and, 116 Disease Control disease definition v., 93–5 weighted kappa for, 118–20 ceftriaxone, for post Lyme disease prevalence and, Brier Score, 147–9, 338–9 syndrome, randomized 94–5 brown belt, 294–5 trials of, 345 ESR and, 92–3 Browner, Warren, 285 CHD. See congenital heart exclusion of intermediate B-type natriuretic peptide disease test results and, 86–97 (BNP), 58–9, 80 chest pain sensitivity in, 81–2, 91–3 classification trees for, 183–4 specificity in, 81–2, 91–3 C. See cost of treating reliability of testing for, tests nonindependence nondisease 333–4 and, 177–8 CACE. See Complier Average chest wall motion, as test for bilirubin, partial verification Causal Effect acute cardiac ischemia, bias and, 83–5 Calibrated Finger Rub Auditory 80, 329 Bland–Altman plot, 128–9, 338 Screening Test chest x-ray, for lung cancer modified, 127–30 (CALFRAST), 327–8 screening, 350–1 variable types and, for calibration, 127–30 CHF. See congestive heart reliability, 110–11 in risk predictions, 146–9 failure 358 © in this web service Cambridge University Press www.cambridge.org Cambridge University Press 978-1-108-43671-7 — Evidence-Based Diagnosis 2nd Edition Index More Information Index chorionic villus sampling conclusions, in diagnostic test congestive heart failure (CHF), (CVS), 5, 93–5, 178–83, studies, 76–80 BNP test in, 58–9, 80 186, 189–91 conditional independence continuous measurements, chromosomal abnormalities, in imperfect gold standard reliability in, 121 fetal, 5, 93–5, 178–83, bias, 89–90 calibration for, 127–30 186, 188–91 of tests, 175 test–retest, 121 classification trees, 181–5 conditional probability, 10 average standard deviation clinical decision making, confidence intervals, 280 and, 123 probability estimates v., for acetaminophen with correlation coefficient and, 312–13 vaccines, 355–6 123–5 clinical decision rules in antidepressant error by magnitude with, clinician v., 198 randomized trials, 125–7 EBM in future, 314–15 353–4 method comparison for, k-fold cross validation in, 196 around ARR, 292–3 127–9 logistic regression in black belt, 295 within-subject standard development of, 192–5 blue belt, 294 deviation/repeatability, overfitting and, 193–6 brown belt, 294–5 122–3 test selection for, 192–6 green belt, 293–4 continuous outcomes, risk clinical experience, statistical white belt, 293 predictions for, 164 expertise v., 304 yellow belt, 293 continuous test, 47 clinical trials, Bayesian analysis background on dichotomous, 47–8 of, 291–2 classical (frequentist) Grim Reaper walking speed, clinician statistics, 281–2 327 autonomy of, 306–7 stochastic and epistemic in hypothetical trial cases, clinical decision rules v., 198 probability, 280–1 326–7 EBM diagnostic errors and, definition of, 289–90 logistic regression for, 308–13 for epidural analgesia and 189–91 CMV. See cytomegalovirus C-section rates, 355 ROC curves in, 51–2 cognitive bias, 311 for Grim Reaper walking AUROC and, 51, 54–5 colic, testing for, 318 speed, 354 information in, 55 college education, age at first in prenatal antidepressant and likelihood ratio birth and, 349 autism studies, 354–5 relationship to, 57–9, colon cancer, screening tests P-values and, 292–3 325–6 for, 269–70 in sentinel-node biopsy optimal cutoffs and, 62–3 community-acquired v. axillary dissection, in signal detection theory, pneumonia, risk 356 49–50 predictions for, 340 for small numerators, for urinalysis, 323–5 comparison group, in 295–6 walking man approach to, randomized trials, 207 confirmation bias, 311 52–4 Complier Average Causal Effect confounding for WBC count in joint (CACE), 234 falsification tests for, 236–8, fluid, 322–3 composite endpoints, 209–10 348 WBC counts and, 48–51, computed tomography (CT), 4 in observational studies, 55 for AAA, reliability of testing 231–3 Wilcoxon Rank Sum test for, 338 propensity scores for, and, 54–5 for body packing, reliability 238–41, 348–9 WBC count, 47–8 of testing for, 333–8 randomized trials for continuous variables, 110–11 for lung cancer screening, minimization of, 205–6 disease definition and, 93, 350–1 in screening tests, 259–60 330 computed tomography confounding by indication, in randomized trials, 215 angiography (CTA), 231–3 cooling, of newborns, 291–2 spectrum bias in, 93 congenital CMV, screening copper standard.